Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial
Titel:
Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial
Auteur:
Hasan, Alkomiet Roeh, Astrid Leucht, Stefan Langguth, Berthold Hansbauer, Maximilian Oviedo-Salcedo, Tatiana Kirchner, Sophie K. Papazova, Irina Löhrs, Lisa Wagner, Elias Maurus, Isabel Strube, Wolfgang Rossner, Moritz J. Wehr, Michael C. Bauer, Ingrid Heres, Stephan Leucht, Claudia Kreuzer, Peter M. Zimmermann, Stephanie Schneider-Axmann, Thomas Görlitz, Thomas Karch, Susanne Egert-Schwender, Silvia Schossow, Beate Rothe, Philipp Falkai, Peter